Is KPRX or KZIA more undervalued in 2026?

CirclFi compares Kiora Pharmaceuticals, Inc. (KPRX) and Kazia Therapeutics Limited (KZIA) using 13 institutional-grade valuation models. KPRX has a Quality of Company score of 5.5/10 while KZIA scores 4.3/10.

Which is a better buy — KPRX or KZIA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do KPRX and KZIA valuations compare?

KPRX at $2.83 and KZIA at $12.67 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

KPRX vs KZIA Valuation Comparison 2026 — Intrinsic Value Analysis

KPRX

Biotechnology

Kiora Pharmaceuticals, Inc.

Quality

5.5

out of 10

Value Trap

LOW

Price

$2.83

Last close

Models

9/13

Active

KZIA

Biotechnology

Kazia Therapeutics Limited

Quality

4.3

out of 10

Value Trap

SAFE

Price

$12.67

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	KPRX Fair Value	KPRX Upside	KZIA Fair Value	KZIA Upside
Bayesian DCF	Intrinsic	$2.06	-27.1%	$5.76	-54.5%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.48	-80.2%	$0.43	-96.7%
Dynamic NAV	Asset-Based	$4.83	+70.8%	$2.95	-76.7%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for KPRX vs KZIA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

KPRX vs KZIA — Which Stock Is More Undervalued?

KPRX scores higher with a 5.5/10 quality rating vs KZIA's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Kiora Pharmaceuticals, Inc. (KPRX) and Kazia Therapeutics Limited (KZIA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

KPRX currently trades at $2.83 with a QOC of 5.5/10, while KZIA trades at $12.67 with a QOC of 4.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).